Chanarat lab

Laboratory of Molecular Medical Mycology, Department of Biochemistry, Faculty of Science, Mahidol University

A multiplexed Cas13-based assay with point-of-care attributes for simultaneous COVID-19 diagnosis and variant surveillance


Journal article


M. Patchsung, A. Homchan, K. Aphicho, S. Suraritdechachai, T. Wanitchanon, A. Pattama, K. Sappakhaw, P. Meesawat, T. Wongsatit, A. Athipanyasilp, K. Jantarug, N. Athipanyasilp, J. Buahom, S. Visanpattanasin, N. Niljianskul, P. Chaiyen, R. Tinikul, N. Wichukchinda, S. Mahasirimongkol, R. Sirijatuphat, N. Angkasekwinai, M. Crone, P. Freemont, J. Joung, A. Ladha, O. Abudayyeh, J. Gootenberg, F. Zhang, C. Chewapreecha, S. Chanarat, N. Horthongkham, D. Pakotiprapha, C. Uttamapinant
medRxiv, 2022

Semantic Scholar DOI
Cite

Cite

APA   Click to copy
Patchsung, M., Homchan, A., Aphicho, K., Suraritdechachai, S., Wanitchanon, T., Pattama, A., … Uttamapinant, C. (2022). A multiplexed Cas13-based assay with point-of-care attributes for simultaneous COVID-19 diagnosis and variant surveillance. MedRxiv.


Chicago/Turabian   Click to copy
Patchsung, M., A. Homchan, K. Aphicho, S. Suraritdechachai, T. Wanitchanon, A. Pattama, K. Sappakhaw, et al. “A Multiplexed Cas13-Based Assay with Point-of-Care Attributes for Simultaneous COVID-19 Diagnosis and Variant Surveillance.” medRxiv (2022).


MLA   Click to copy
Patchsung, M., et al. “A Multiplexed Cas13-Based Assay with Point-of-Care Attributes for Simultaneous COVID-19 Diagnosis and Variant Surveillance.” MedRxiv, 2022.


BibTeX   Click to copy

@article{m2022a,
  title = {A multiplexed Cas13-based assay with point-of-care attributes for simultaneous COVID-19 diagnosis and variant surveillance},
  year = {2022},
  journal = {medRxiv},
  author = {Patchsung, M. and Homchan, A. and Aphicho, K. and Suraritdechachai, S. and Wanitchanon, T. and Pattama, A. and Sappakhaw, K. and Meesawat, P. and Wongsatit, T. and Athipanyasilp, A. and Jantarug, K. and Athipanyasilp, N. and Buahom, J. and Visanpattanasin, S. and Niljianskul, N. and Chaiyen, P. and Tinikul, R. and Wichukchinda, N. and Mahasirimongkol, S. and Sirijatuphat, R. and Angkasekwinai, N. and Crone, M. and Freemont, P. and Joung, J. and Ladha, A. and Abudayyeh, O. and Gootenberg, J. and Zhang, F. and Chewapreecha, C. and Chanarat, S. and Horthongkham, N. and Pakotiprapha, D. and Uttamapinant, C.}
}

Abstract

Point-of-care (POC) nucleic acid detection technologies are poised to aid gold-standard technologies in controlling the COVID-19 pandemic, yet shortcomings in the capability to perform critically needed complex detection, such as multiplexed detection for viral variant surveillance, may limit their widespread adoption. Herein, we developed a robust multiplexed CRISPR-based detection using LwaCas13a and PsmCas13b to simultaneously diagnose SARS-CoV-2 infection and pinpoint the causative SARS-CoV-2 variant of concern (VOC)-including globally dominant VOCs Delta (B.1.617.2) and Omicron (B.1.1.529)-all while maintaining high levels of accuracy upon the detection of multiple SARS-CoV-2 gene targets. The platform has several attributes suitable for POC use: premixed, freeze-dried reagents for easy use and storage; convenient direct-to-eye or smartphone-based readouts; and a one-pot variant of the multiplexed detection. To reduce reliance on proprietary reagents and enable sustainable use of such a technology in low- and middle-income countries, we locally produced and formulated our own recombinase polymerase amplification reaction and demonstrated its equivalent efficiency to commercial counterparts. Our tool, CRISPR-based detection for simultaneous COVID-19 diagnosis and variant surveillance which can be locally manufactured, may enable sustainable use of CRISPR diagnostics technologies for COVID-19 and other diseases in POC settings.


Share



Follow this website


You need to create an Owlstown account to follow this website.


Sign up

Already an Owlstown member?

Log in